SK Bio's 2020 Plans Undeterred By Pandemic
US Launch, IPO Moving Ahead
The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.
You may also be interested in...
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
SK Biopharmaceuticals receives US approval for novel anti-epileptic drug, marking a major milestone for the South Korean firm in its goal of becoming a fully integrated global pharma and potentially boosting its huge planned IPO. Through its US subsidiary, the SK Group company will independently market and sell the product in the world’s biggest single market.